Vortioxetina

Brintellix

Bibliografia - Quali fonti bibliografiche per Vortioxetina?

1. Agenzia Italiana del Farmaco – AIFA, Brintellix – Riassunto delle caratteristiche del Prodotto, 2021, 7 agosto (https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/).


2. Andrade C., J. Clin. Psychiatry, 2022, 83 (4), 22f14593.


3. Baldwin D.S. et al., Int. Clin. Psychopharmacol., 2012, 27 (4), 197.


4. Baldwin D.S. et al., Eur. Neuropsychopharmacol., 2012a, 22 (7), 482.


5. Baldwin D.S. et al., J, Psychopharmacol., 2016, 30 (3), 242.


6. Baune B.T. et al., Int. J. Neuropsypharmacol., 2018, 21 (2), 97.


7. Bidzan L. et al., Eur. Neuropsychopharmacol., 2012, 22 (12), 847.


8. Borhannejad F. et al., J. Clin. Pharm. Ther., 2020, 45 (4), 804.


9. Bull S.A. et al., Ann. Pharmacother., 2002, 36 (4), 578.


10. Carvalho A.F. et al., Psychother. Psychosom., 2016, 85, 270.


11. Cipriani A. et al., lancet, 2018, 391 (10128), 1357.


12. Chen G. et al., J. Clin. Pharmacol., 2011, 51, 1350.


13. Chen G. et al., Clin. Pharm. Ther., 2012, 91 (Suppl 1), S39.


14. Chen G. et al., Clin. Drug Investig., 2013, 33 (10), 727.


15. Chen G. et al., J. Clin. Pharmacol., 2015, 55 (6), 671.


16. Chen G. et al., Clin. Pharmacokinet., 2016, 55 (9), 1115.


17. Christensen M.C. et al., CNS Spectr., 2019, 24 (2), 249.


18. Christensen M.C. et al., J. Psychopharmacol., 2022, 36 (5), 566.


19. Clayton A.H. et al., J. Clin. Psychiatry, 2002, 63 (4), 357.


20. Cuomo A et al., Rivista Società Italiana di Medicina Generale, 2019, n 5, vol 26, 32.


21. Cuomo A. et al., Prim. Care Companion CNS Disord., 2022, 24 (3), 21m03078.


22. Ekhart C. et al., Drug Saf., 2022, 45 (2), 145.


23. Findling R.L. et al., J. Am. Acad. Child. Adolesc. Psychiatry, 2022, 61 (9), 1106.


24. Food and Drug Administration – FDA, Trintellix – Prescribing Information, 2021, https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/204447s024lbl.pdf


25. Heiser J.F. et al., CNS Drugs, 1998, 10 (5), 343.


26. Hetrick S.E. et al., Cochrane database Syst. Rev., 2021, 5 (5), CD013674.


27. Hvenegaard M.G. et al., Drug Metab. Dispos., 2012, 40 (7), 1357.


28. Jacobsen P.L. et al., CNS Spectr., 2020, 25 (1), 50.


29. Katona C. et al., Int. Clin. Psychopharmacol., 2012, 27 (4), 2015.


30. Lactmed, Vortioxetine, 2022, 18 aprile https://www.ncbi.nlm.nih.gov/books/NBK500835/


31. Li Y. Neuropharmacology, 2017, 15, 121.


32. Mahableshwarkar A.R. et al., Hum Psychopharmacol., 2014, 29 (1), 64.


33. Mahableshwarkar A.R. et al., Int. J. Clin. Pract., 2014a, 68 (1), 49.


34. Marshall K. et al., Breastfeed Med., 2021, 16, 843.


35. Mayer M. et al., Clin. Pharmacol. Drug Dev., 2012, 1, 188.


36. Mazza M.G. et al. Medicine (Baltimore), 2018, 97(25), e10788.


37. McIntyre R.S. et al., Int. J. Neuropsychopharmacol., 2014, 17 (10), 1557.


38. Meeusen R. et al., Sports Med., 2006, 36 (10), 881.


39. Mnie-Filali O. et al., Neuropsychopharmacology, 2011, 36 (6), 1275.


40. Monfort A. et al., J. Pharm. Biomed. Anal., 2021, 204, 114236.


41. Papalexi E. et al., BMC Psychiatry, 2022, 22 (1), 548.


42. Sanchez C. et al., Pharmacol. Ther., 2015, 145, 43.


43. Schatzberg A.F. et al., J. Clin. Psychiatry, 2014, 75 (12), 1411,


44. Sowa-Kucma M. et al., Pharmacol. Rep., 2017, 69 (4), 595.


45. Spina E., Santoro V., Riv. Psichiatr., 2015, 50 (5), 210.


46. Thase M.E. et al., Eur. Neuropsychopharmacol., 2016, 26 (6), 979.


47. Thase M.E. et al., J. Affect Disord., 2022, 303, 123.


48. Theunissen E.L. et al., Clin. Pharmacol. Ther., 93 (6), 493


49. Uher R. et al., Br. J. Psychiatry, 2009, 195 (3), 202.


50. Uljon S. et al., Clin. Chim. Acta, 2019, 99, 1-


51. Vieta E. et al., Eur. Neuropsychopharmacol., 2017, 27 (9), 877.


52. Wang Y. et al., Clin. Pharm. Ther., 2011, 89 (Suppl 1), S71.


53. WHO Pharmaceuticals Newsletter, 2019, n 5, 19 https://apps.who.int/iris/bitstream/handle/10665/329688/WPN-2019-05-eng.pdf?sequence=1&isAllowed=y.


54. Wilson S. et al., J. Psychopharmacol., 29 (10), 1085.